LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

Neoadjuvant Therapy
DOI: 10.1016/j.annonc.2024.08.2263 Publication Date: 2024-09-17T21:04:02Z